Paolo Pertile
Paolo Pertile
Verified email at
Cited by
Cited by
Should current criteria for detecting and repairing arteriovenous fistula stenosis be reconsidered? Interim analysis of a randomized controlled trial
N Tessitore, V Bedogna, A Poli, G Lipari, P Pertile, E Baggio, A Contro, ...
Nephrology Dialysis Transplantation 29 (1), 179-187, 2014
A Bayesian decision theoretic model of sequential experimentation with delayed response
S Chick, M Forster, P Pertile
Journal of the Royal Statistical Society. Series B (Statistical Methodology …, 2017
Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies
P Pertile, M Forster, DL Torre
Journal of the Royal Statistical Society Series A: Statistics in Society 177 …, 2014
The impact of managed entry agreements on pharmaceutical prices
S Gamba, P Pertile, S Vogler
Health Economics 29, 47-62, 2020
Static and dynamic efficiency of irreversible health care investments under alternative payment rules
R Levaggi, M Moretto, P Pertile
Journal of Health Economics 31 (1), 169-179, 2012
Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective
M Forster, P Pertile
Health Economics 22 (12), 1507-1514, 2013
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography
P Pertile
International journal of health care finance and economics 9, 317-332, 2009
The dynamics of pharmaceutical regulation and R&D investments
R Levaggi, M Moretto, P Pertile
Journal of Public Economic Theory 19 (1), 121-141, 2017
Late-stage pharmaceutical R&D and pricing policies under two-stage regulation
S Jobjörnsson, M Forster, P Pertile, CF Burman
Journal of health economics 50, 298-311, 2016
Investment in health technologies in a competitive model with real options
P Pertile
Journal of Public Economic Theory 10 (5), 923-952, 2008
A large scale OLG model for the analysis of the redistributive effects of policy reforms
A Bucciol, L Cavalli, I Fedotenkov, P Pertile, V Polin, N Sartor, ...
European Journal of Political Economy 48, 104-127, 2017
Two-part payments for the reimbursement of investments in health technologies
R Levaggi, M Moretto, P Pertile
Health Policy 115 (2-3), 230-236, 2014
Value-based pricing alternatives for personalised drugs: implications of asymmetric information and competition
R Levaggi, P Pertile
Applied Health Economics and Health Policy 18 (3), 357-362, 2020
The timing of adoption of positron emission tomography: a real options approach
P Pertile, E Torri, L Flor, S Tardivo
Health care management science 12, 217-227, 2009
Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy
P Pertile, A Poli, L Dominioni, N Rotolo, E Nardecchia, M Castiglioni, ...
Cost Effectiveness and Resource Allocation 13 (1), 1-12, 2015
Which valued‐based price when patients are heterogeneous?
R Levaggi, P Pertile
Health economics 29 (8), 923-935, 2020
Redistribution at the local level: the case of public childcare in Italy
A Bucciol, L Cavalli, P Pertile, V Polin, A Sommacal
International Review of Economics 63, 359-378, 2016
L’ISEE in Italia: Una nota metodologica partendo dai dati IT-SILC
A Bucciol, L Cavalli, E Dalla Chiara, M Menon, P Pertile, V Polin, ...
University of Verona, Department of Economics Working Papers, 2014
Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial
M Forster, S Brealey, S Chick, A Keding, B Corbacho, A Alban, P Pertile, ...
Clinical trials 18 (6), 647-656, 2021
R&D and market size: Who benefits from orphan drug legislation?
S Gamba, L Magazzini, P Pertile
Journal of Health Economics 80, 102522, 2021
The system can't perform the operation now. Try again later.
Articles 1–20